Alexandra Hinniger

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Discovery and Characterization of Zilurgisertib, a Potent and Selective Inhibitor of Activin Receptor-like Kinase‑2 (ALK2) for the Treatment of Fibrodysplasia Ossificans Progressiva.

Discovery and Characterization of Zilurgisertib, a Potent and Selective Inhibitor of Activin Receptor-like Kinase‑2 (ALK2) for the Treatment of Fibrodysplasia Ossificans Progressiva.

Journal: ACS medicinal chemistry letters

Published: August 27, 2025

Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".

Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".

Journal: Journal of medicinal chemistry

Published: April 01, 2025

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.

Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.

Journal: Journal of medicinal chemistry

Published: March 04, 2025

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.

Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.

Journal: Journal of medicinal chemistry

Published: November 22, 2024

Development of a p62 biodegrader for autophagy targeted degradation.

Development of a p62 biodegrader for autophagy targeted degradation.

Journal: Nature communications

Published: October 21, 2024

Dual BACH1 regulation by complementary SCF-type E3 ligases.

Dual BACH1 regulation by complementary SCF-type E3 ligases.

Journal: Cell

Published: March 08, 2024

Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.

Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.

Journal: Journal of medicinal chemistry

Published: January 04, 2024

Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.

Crystal Structure of NLRP3 NACHT Domain With an Inhibitor Defines Mechanism of Inflammasome Inhibition.

Journal: Journal of molecular biology

Published: August 13, 2021

PAX8 and MECOM are interaction partners driving ovarian cancer.

PAX8 and MECOM are interaction partners driving ovarian cancer.

Journal: Nature communications

Published: July 27, 2020

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal: Journal of medicinal chemistry

Published: February 22, 2020

Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.

Journal: ACS medicinal chemistry letters

Published: July 15, 2019

Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM.

Molecular basis for AU-rich element recognition and dimerization by the HuR C-terminal RRM.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 06, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026